Pyxis Oncology Inc. (PYXS)
Pyxis Oncology Statistics
Share Statistics
Pyxis Oncology has 59.47M shares outstanding. The number of shares has increased by 4.59% in one year.
| Shares Outstanding | 59.47M |
| Shares Change (YoY) | 4.59% |
| Shares Change (QoQ) | 3.57% |
| Owned by Institutions (%) | 51.94% |
| Shares Floating | 43.77M |
| Failed to Deliver (FTD) Shares | 127 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 7.42M, so 12.49% of the outstanding shares have been sold short.
| Short Interest | 7.42M |
| Short % of Shares Out | 12.49% |
| Short % of Float | 18.05% |
| Short Ratio (days to cover) | 8.86 |
Valuation Ratios
The PE ratio is -1.18 and the forward PE ratio is -1.2. Pyxis Oncology's PEG ratio is 0.04.
| PE Ratio | -1.18 |
| Forward PE | -1.2 |
| PS Ratio | 5.65 |
| Forward PS | 0.7 |
| PB Ratio | 0.76 |
| P/FCF Ratio | -1.57 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pyxis Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.49, with a Debt / Equity ratio of 0.17.
| Current Ratio | 7.49 |
| Quick Ratio | 7.49 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -0.31 |
| Debt / FCF | -0.35 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $366.95K |
| Profits Per Employee | $-1.76M |
| Employee Count | 44 |
| Asset Turnover | 0.1 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.16M |
| Effective Tax Rate | 2.72% |
Stock Price Statistics
The stock price has increased by -81.71% in the last 52 weeks. The beta is 1.11, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | -81.71% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 2.61 |
| Relative Strength Index (RSI) | 37.68 |
| Average Volume (20 Days) | 599.9K |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of 16.15M and earned -77.33M in profits. Earnings per share was -1.32.
| Revenue | 16.15M |
| Gross Profit | 15.67M |
| Operating Income | -89.46M |
| Net Income | -77.33M |
| EBITDA | -65.51M |
| EBIT | -68.5M |
| Earnings Per Share (EPS) | -1.32 |
Balance Sheet
The company has 19.47M in cash and 20.2M in debt, giving a net cash position of -727K.
| Cash & Cash Equivalents | 19.47M |
| Total Debt | 20.2M |
| Net Cash | -727K |
| Retained Earnings | -363.56M |
| Total Assets | 157.18M |
| Working Capital | 114.76M |
Cash Flow
In the last 12 months, operating cash flow was -57.67M and capital expenditures -237K, giving a free cash flow of -57.91M.
| Operating Cash Flow | -57.67M |
| Capital Expenditures | -237K |
| Free Cash Flow | -57.91M |
| FCF Per Share | -0.99 |
Margins
Gross margin is 97.06%, with operating and profit margins of -554.07% and -478.95%.
| Gross Margin | 97.06% |
| Operating Margin | -554.07% |
| Pretax Margin | -492.35% |
| Profit Margin | -478.95% |
| EBITDA Margin | -405.76% |
| EBIT Margin | -554.07% |
| FCF Margin | -358.66% |
Dividends & Yields
PYXS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PYXS is $10, which is 963.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 963.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -2.78 |
| Piotroski F-Score | 3 |